Since patients who developed EGFR mutant lung adenocarcinomas with acquired resistance to EGFR inhibitor drugs (gefitinib or erlotinib) exhibit increased copy numbers of MET, c-Met-HGF inhibitors are used for lung cancer treatment alone or in combination with other drugs [148]. This evidence concerns the gene MET and lung carcinoma.